Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
作者： Helio S. Sader , Mariana Castanheira , Rodrigo E. Mendes , Robert K. Flamm , David J. Farrell
DOI: 10.1128/AAC.05024-14
关键词: Biology 、 Microbiology 、 Tazobactam 、 Meropenem 、 Ceftazidime/avibactam 、 Piperacillin 、 Multidrug resistant Pseudomonas aeruginosa 、 Ceftazidime 、 Broth microdilution 、 Pseudomonas aeruginosa
摘要: Pseudomonas aeruginosa isolates (n = 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of strains susceptible (MIC, ≤8 μg/ml) to ceftazidime-avibactam, while rates susceptibility for ceftazidime, meropenem, piperacillin-tazobactam 83.8, 81.9, 78.5%, respectively. Multidrug-resistant extensively drug-resistant phenotypes observed in 14.9 8.7% strains, respectively, 81.0 73.7%
sci-hub.se 参考文章(16)
David M. Shlaes, New β-lactam-β-lactamase inhibitor combinations in clinical development Annals of the New York Academy of Sciences. ,vol. 1277, pp. 105- 114 ,(2013) , 10.1111/NYAS.12010
Tiffany R. Keepers, Marcela Gomez, Chris Celeri, Wright W. Nichols, Kevin M. Krause, Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. ,vol. 58, pp. 5297- 5305 ,(2014) , 10.1128/AAC.02894-14
Elena B.M. Breidenstein, César de la Fuente-Núñez, Robert E.W. Hancock, Pseudomonas aeruginosa: all roads lead to resistance Trends in Microbiology. ,vol. 19, pp. 419- 426 ,(2011) , 10.1016/J.TIM.2011.04.005
D.M. Richards, R.N. Brogden, Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. ,vol. 29, pp. 105- 161 ,(1985) , 10.2165/00003495-198529020-00002
Robert K. Flamm, Gregory G. Stone, Helio S. Sader, Ronald N. Jones, Wright W. Nichols, Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value Journal of Chemotherapy. ,vol. 26, pp. 333- 338 ,(2014) , 10.1179/1973947813Y.0000000145
Ken Coleman, Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors Current Opinion in Microbiology. ,vol. 14, pp. 550- 555 ,(2011) , 10.1016/J.MIB.2011.07.026
Philip D. Lister, Daniel J. Wolter, Nancy D. Hanson, Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms Clinical Microbiology Reviews. ,vol. 22, pp. 582- 610 ,(2009) , 10.1128/CMR.00040-09
Dawn M Sievert, Philip Ricks, Jonathan R Edwards, Amy Schneider, Jean Patel, Arjun Srinivasan, Alex Kallen, Brandi Limbago, Scott Fridkin, Antimicrobial-Resistant Pathogens Associated with Healthcare- Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 Infection Control and Hospital Epidemiology. ,vol. 29, pp. 996- 1011 ,(2008) , 10.1086/591861
D. M. Livermore, Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare? Clinical Infectious Diseases. ,vol. 34, pp. 634- 640 ,(2002) , 10.1086/338782
A. Walkty, M. DeCorby, P. R. S. Lagacé-Wiens, J. A. Karlowsky, D. J. Hoban, G. G. Zhanel, In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study) Antimicrobial Agents and Chemotherapy. ,vol. 55, pp. 2992- 2994 ,(2011) , 10.1128/AAC.01696-10